HIV drug could be made for just $40 a year for every patient

Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make it available at a thousand times less than that price worldwide.

UNAids said it could “herald a breakthrough for HIV prevention” if the drug was available “rapidly and affordably”.

Given by injection every six months, lenacapavir can prevent infection and suppress HIV in people who are already infected.

In a trial, the drug offered 100% protection to more than 5,000 women in South Africa and Uganda, according to results announced by Gilead last month.